8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Feb 3, 2009)

Filed February 3, 2009For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K report on February 3, 2009, to announce its financial results for the fourth quarter and full year ended December 31, 2008. The report primarily serves to furnish a press release containing these financial details, as well as provide information on the company's operations and financial condition. Investors should note that while most of the press release is furnished, specific sections, including the initial paragraphs and those following "Twelve-Month Results," are considered "filed" under the Securities Exchange Act of 1934. This filing is critical for understanding the company's recent performance and financial standing heading into the new fiscal year. The core of this filing is the attached press release (Exhibit 99.1), which details the company's performance for the fourth quarter and the entirety of 2008. Investors interested in Edwards Lifesciences' trajectory, profitability, and key financial metrics would find this press release to be the primary source of actionable information derived from this 8-K filing. The report also confirms the roles and responsibilities of key financial personnel, such as the Chief Financial Officer.

Key Highlights

  • 1Edwards Lifesciences announced its fourth quarter and full year 2008 financial results on February 3, 2009, via an 8-K filing.
  • 2The filing's primary purpose is to furnish a press release detailing the company's financial performance.
  • 3Key financial results for Q4 2008 and the full year 2008 are contained within the attached press release (Exhibit 99.1).
  • 4Specific portions of the press release are deemed 'filed' with the SEC, impacting their legal implications under the Exchange Act.
  • 5The report confirms the CFO, Thomas M. Abate, as an authorized signatory.
  • 6Investors can use this filing to assess the company's performance and financial condition at the close of 2008.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce and provide investors with Edwards Lifesciences' financial results for the fourth quarter and the full year of 2008, as detailed in an attached press release.

The specific financial results for the fourth quarter and full year 2008 are located in Exhibit 99.1, which is the press release dated February 3, 2009, attached to this 8-K filing.

No, not all parts of the press release are considered 'filed' under the Securities Exchange Act of 1934. Only the information contained in the first two paragraphs and the two paragraphs immediately following 'Twelve-Month Results' on pages 6 through 10 of the press release are deemed filed.

The report is signed by Thomas M. Abate, Corporate Vice President, Chief Financial Officer, and Treasurer, indicating his authorization for this filing.